Acrivon Therapeutics, Inc. (ACRV) stock
ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $61.28MP/E –Yield –
Acrivon Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Acrivon Therapeutics's enterprise value was -$22.69M on Nov 11, 2026, against -$54.80M a year earlier. Over the last 4 years it ranged from -$135.76M to $317.67M, with a median of -$22.69M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$22.69M | – |
| 2025 | Dec 31, 2025 | -$53.22M | – |
| 2024 | Dec 31, 2024 | -$45.03K | – |
| 2023 | Dec 29, 2023 | -$33.34M | – |
| 2022 | Dec 30, 2022 | -$56.13M | – |
See a number that looks wrong?